Triple-negative breast cancer (TNBC) is an aggressive type of invasive breast cancer and is known to be one of the deadliest versions of the disease as it can grow and spread faster, has fewer treatment options and tends to have a worse prognosis than its counterparts.

Moreover, TNBC cancer tumors lacks the hormone receptors that allow many other breast cancers to be treated with targeted drugs. While some patients initially respond to therapy, the disease frequently returns and is often more resistant the second time.

However, scientists at the Medical University of South Carolina have now developed an antibody that can potentially slow the growth of primary tumors, reduce the spread of cancer to the lungs and revive immune cells that normally attack cancer.

Initial testing also showed that this experimental treatment also killed cancer cells that no longer responded to chemotherapy.

MUSC surgical resident Dr Lillian Hsu said: "TNBC is so hard to treat, and so many therapies come with serious toxicities, so finding a way to activate the immune system without adding new side effects is especially meaningful."

How Does The Antibody Work?

Initially, the scientists recognized a protein called secreted frizzled-related protein 2 (SFRP2), which helps cancerous tumours thrive by encouraging the formation of new blood vessels, preventing cancer cells from dying and weakening immune cells that would otherwise help eliminate the disease.

Dr Nancy Klauber-DeMore, a breast surgical oncologist who co-leads the Developmental Cancer Therapeutics Research Program at Hollings and spent 20 years analyzing SFRP2, said: "My lab first identified the role of SFRP2 in breast cancer in 2008. Since then, we've discovered its mechanism of action in breast cancer growth, metastasis and immune exhaustion and developed an antibody to block SFRP2.

"This is the first time anyone has demonstrated that SFRP2 is expressed on tumor-associated macrophages. That finding alone opens up an entirely new way of understanding and potentially manipulating the immune microenvironment."

The animal study, which was published in Breast Cancer Research, focused on building an antibody that counteracts the effects of SFRP2 and as a result, slows the development of TNBC.

After multiple treatments were tested on mice, the scientists found that their antibody helps retrain the immune system to respond to cancer at later stages as well as strengthen immune defenses that are typically weakened in cancer and potentially improve responses to immunotherapy.

Triple-Negative Breast Cancer: What You Should Know

Symptoms for TNBC include:

• A new lump or mass in your breast
• Breast pain or nipple pain
• Dimpled breast skin
• Nipple discharge
• A nipple turning inward
• Nipple or breast skin that’s dry, flaking, thickened or red
• Swelling in all or part of your breast
• Swollen lymph nodes under your arm or near your collarbone

According to the Cleaveland Clinic, the overall survival rate for women with TNBC is about 77 percent as likely as females who don’t have TNBC to live for at least five years after receiving a diagnosis.

While surgery is the most common form of treatment for TNBC, oncologists may also recommend chemotherapy, radiation, immunotherapy and antibody drug conjugates.

TNBC accounts for about 10-15 percent of all breast cancer cases and tends to be more common in women younger than age 40 and those who have a BRCA1 mutation.

The US Food and Drug Administration approved leucovorin, but not for what White House had recommended for in its September briefing. FDA has approved the prescription drug leucovorin for cerebral folate deficiency in the receptor 1 gene, a genetic condition that is estimated to affect only about 1 in 1 million people.

In September, the White House touted leucovorin as a potential treatment for children with autism. Health and Me previously reported on how parents were struggling to find the prescription drug, while not enough scientific evidence was there to support the claim.

What Is Leucovorin?

It is a high-dose B vitamin, which is commonly used as a treatment to counteract the side effects of chemotherapy. It has been approved by the FDA for cerebral folate deficiency in the receptor 1 gene. The disease is rare and fewer than 50 cases have been identified worldwide. FDA Commissioner Dr Marty Makary called this approval "a significant milestone" for patients with the condition.

However, in September last year, Markary and US Health and Human Services Secretary Robert F Kennedy Jr said that the drug could help children with autism. Kennedy, standing next to US President Donald Trump, said, they had "identified an exciting therapy that may benefit large number of children who suffer from autism."

CNN reported that in Austin, Texas, Meagan Johnson, a mother with an autistic son of three years of age, spent four days calling pharmacies across the region searching for leucovorin. She contacted nearly 40 pharmacies around her home in Pflugerville, hoping to locate the medication. Health and Me reported how getting the prescription turned out to be far harder than obtaining it.

This update on leucovorin, notes CNN have hit some families hard, especially the families of children with autism. This is because of the September briefing and when Trump also said that painkiller Tylenol could in fact cause autism. The drug leucovorin was used as something that could give them hope, however, with the update in its label, parents efforts to find the prescription drugs could feel like in vain.

The Rare Condition For Which Drug Got Its Approval

The drug got its approval for folate deficiency in the receptor 1 gene. This is a defect that causes proteins that guide folate into the brain to malfunction. As a result, normal levels of folate is found in the blood, but not in the brain or nervous system, due to which tasks like thinking, speech and movement could not be performed.

In an op/ed published in Politico and reposted on the White House website last fall, Markary said that his agency would "approve prescription leucovorin as a treatment for children with cerebral folate deficiency and autistic symptoms". However, he did not that it cause not a cure for autism, but there have been studies that show that it could help children with folate deficiency and autism to improve speech by roughly 60 per cent. The Trump administration made a bold move to expand the usage of the drug by "opening the door to the first FDA-recognized treatment for autism." wrote Markary and other HHS leaders.

All India Institute of Medical Sciences (AIIMS) and the Indian Space Research Organisation (ISRO) signed a Memorandum of Understanding (MoU) on Monday to collaborate on advancing research in space medicine.

The MoU was signed between M Srinivas, Director (AIIMS), New Delhi and Dinesh Kumar Singh, Director, Human Space Flight Centre (HSFC), ISRO. The event brought together senior leadership from AIIMS and ISRO, including ISRO Chairman V Narayanan and Secretary, Department of Space, as well as Deans, Heads of Departments, faculty members, and studies from AIIMS New Delhi.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the news agency Asian News International (ANI), a press release of the collaboration noted for a cooperative framework for ground-based and space-based research in Space Medicine. The press release also noted that the research will cover areas like human physiology, cardiovascular and autonomic regulation, musculoskeletal health in microgravity, microbiome and immunology, genomics and biomarkers and behavioral health.

“This MoU will give us the escape velocity to venture together into the field of space medicine. Collaborative research between AIIMS and ISRO will benefit patients, the nation, and ultimately humankind. As India moves toward Viksit Bharat by 2047, we hope to emerge as a Vishwaguru in space medicine as well,” said Prof M Srinivas, Director, AIIMS, New Delhi.

Chairman of ISRO Dr V Narayanan and Secretary, Department of Space also highlighted India’s remarkable journey in space programme. He noted how India evolved from the time when rockets and equipment were transported on bicycles and bullock carts to today, where it is going to be leading medical and research institutions like AIIMS to strengthen India’s human spaceflight capabilities.

The programme also featured a presentation on AIIMS New Delhi’s ongoing work in space medicine research, delivered by Prof. KK Deepak, former Head of the Department of Physiology. The event was attended by Heads of Departments and faculty members from across AIIMS New Delhi, along with representatives from the Resident Doctors Association (RDA), the AIIMS Student Association (ASA), and the Society of Young Scientists (SYS).

The collaboration represents an important step toward enhancing India’s capabilities in human spaceflight and biomedical research. It also aligns with the country’s broader scientific ambitions as India moves toward its centenary in 2047 and the vision of Viksit Bharat.

Read: Sunita Williams Retires After 27 Years: Health Challenges She Faced After Spending 600+ Days in Space

What Do We Already Know About Space Medicine?

As per a 2017 study in the British Journal of Anaesthesia, space medicine is fundamental to the human exploration of space. It supports survival, function and performance in this challenging as potentially lethal environment. It is international, intercultural and interdisciplinary, operating at the boundaries of exploration, science, technology and medicine.

Space medicine specialists play a crucial role in safeguarding astronauts and other spaceflight participants. Known as “flight surgeons,” they help develop strategies to protect the health, safety, and performance of space travellers in the extreme conditions of space. Their responsibilities span every stage of a mission — from selection and training to in-flight care, post-mission rehabilitation, and monitoring long-term health effects.

With inputs from ANI

Sick days are again piling up with a respiratory disease, not COVID-19 or the flu. This disease is most likely the one Americans have not heard of. This is HMPV or human metapneumovirus. Doctors have asked people to stay vigilant as seasonal flu virus could lead to pneumonia and bronchitis, and it is spreading in California wastewater and around the country. However, as per public health officials, there is nothing to get worried at this point.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the public database WasterwaterScan Dashboard, high levels of HMPV were detected across Northern California cities. The highest levels were reported in Redwood City, whereas elevated levels were found in San Francisco Bay Area and Napa's Wine Country. What's more dangerous is that this virus is without a vaccine.

The good news is that in other parts of country HMPV remains lower. However, the Centers for Disease Control and Prevention (CDC) noted that data from October 2025 shows the cases are trending up, especially during winter and spring.

Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic, as reported by The Independent said, "In the late winter, early spring, it can account for five percent to 10 percent of all the respiratory infections that we diagnose in the United States. So it's definitely out there." Experts explain that other viruses like HMPV or influenza get a chance when COVID is quieter.

Read: HMPV Virus Cases Surging In California, New Jersey: Is It Dangerous?

Virus Without A Vaccine: What Is HMPV?

HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).

HMPV most likely spreads from an infected person to others through:

• the air by coughing and sneezing
• close personal contact, such as touching or shaking hands
• touching objects or surfaces that have the viruses on them, then touching the mouth, nose, or eyes

In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.

The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:

• cough
• fever
• nasal congestion
• shortness of breath

People at risk include:

• elderly people
• children
• people with comorbidities

"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.

“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.

While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:

Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.

Why Are People Hearing About The Virus Without Vaccine Now?

The reason people have not heard about it before is because its symptoms are nearly indistinguishable from other respiratory infections, so often it could go undiagnosed. Furthermore, earlier the COVID cases and influenza cases sparked up, which deviated the attention from HMPV. Now, with the season gone, and increased awareness around respiratory illnesses, greater attention to viruses like HMPV is also paid.